免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

一种新型三基因敲除同种异体 BCMA CAR-T 细胞疗法（CT0590）用于多发性骨髓瘤：临床前及 1 期研究

A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.

原发性浆细胞白血病

Primary Plasma Cell Leukemia.

多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性：EADV 工作组立场文件与实践建议

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

优化 BCMA 靶向 T 细胞衔接疗法在三类暴露的复发/难治性多发性骨髓瘤患者中的真实世界应用：意大利改良德尔菲共识

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: A

在本文中，我们探讨了抗 BCMA BsAb 在 TCE RRMM 患者中真实世界应用相关的主要挑战，并提供专家建议，以补充现有指南并支持临床实践。

复发/难治性多发性骨髓瘤中双特异性抗体与 CAR-T 细胞治疗的真实世界分析：全球 TriNetX 发现与当代验证队列

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemp

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

疾病生物学与桥接策略对复发/难治性多发性骨髓瘤 CAR-T 细胞治疗后结局的影响

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.